Case Type: Mergers & Acquisitions

Synlogic, Inc. (OTC: SYBX) related to its merger with Caldera Therapeutics, Inc. Upon closing of the proposed transaction, Synlogic shareholders are expected to own approximately 2.3% of the combined company.

DoubleVerify Holdings, Inc. (NYSE: DV) related to its sale to Nielsen Holdings. Under the terms of the proposed transaction, shareholders of DoubleVerify will receive $13.60 in cash for each share of DoubleVerify that they own.

Sunrise Realty Trust, Inc. (NasdaqCM: SUNS) related to its merger with Southern Realty Trust Inc. Upon closing of the proposed transaction, Sunrise Realty shareholders are expected to own approximately 62% of the combined company.

Bowman Consulting Group Ltd. (NasdaqGM: BWMN) related to its sale to Bernhard Capital Partners. Under the terms of the proposed transaction, shareholders of Bowman will receive $43.00 in cash for each share of Bowman that they own.

Cherry Hill Mortgage Investment Corporation (NYSE: CHMI) related to its sale to TPG Mortgage Investment Trust, Inc. Under the terms of the proposed transaction, shareholders of Cherry Hill will receive 0.3063 shares of TPG Mortgage common stock and $0.93 in cash for each share of Cherry Hill that they own.

Varex Imaging Corporation (Nasdaq: VREX) related to its sale to Teledyne Technologies Incorporated for $18.90 per share in cash.

Harte Hanks, Inc. (Nasdaq: HHS) related to its sale to Star Equity Holdings, Inc. Under the terms of the proposed transaction, Harte Hanks shareholders may elect to receive either (1) $5.00 in cash for each Harte Hanks share, or (2) 0.50 shares of Star Equity’s publicly traded 10% Series A Cumulative Perpetual Preferred Stock for … Read more

Accelerant Holdings (NYSE: ARX) related to its sale to Thoma Bravo. Under the terms of the proposed transaction, Accelerant Holdings shareholders will get $20.25 per each share they own.

Werewolf Therapeutics, Inc. (Nasdaq: HOWL) related to its sale to Ambros Therapeutics, Inc. Under the terms of the proposed transaction, both companies will combine in an all-stock transaction. The combined company will focus on advancing Ambros Therapeutics’ neridronate development program in Complex Regional Pain Syndrome Type 1 (“CRPS-1”, formerly known as Reflex Sympathetic Dystrophy). Upon … Read more

MarineMax, Inc. (NYSE: HZO) related to its sale to Francisco Partners. Under the terms of the proposed transaction, MarineMax shareholders will receive $53.00 per share in an all-cash transaction valued at approximately $1.5 billion. MarineMax insiders will receive substantial benefits as part of change of control arrangements.